Ozempic ‘Oops' Babies Spark Debate About Weight-Loss Shot Use as Fertility Drugs [BNN Bloomberg (Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: BNN Bloomberg
That's leading to questions about the safety of medications from Novo Nordisk A/S and Eli Lilly & Co. during pregnancy. “I thought I couldn't have any more kids,” said Torria Leggett, 40, who had been trying for another after her first child was born in 2018. In 2022, the social worker from Whiteville, North Carolina, began taking Novo's Ozempic to treat obesity, then switched to Lilly's Mounjaro. As the pounds melted off, there was soon another reason to celebrate. She was expecting. “The weight loss, that's likely what jump-started it,” she said. “I couldn't believe it.” Stories like these are encouraging doctors to use GLP-1 drugs to treat polycystic ovary syndrome, one of the leading causes of infertility in US women. Yet they're doing so without much data on the drugs' impact on pregnancy. “The ‘oops' babies on Ozempic and Wegovy are happening all over the place,” said Melanie Cree, director of the PCOS clinic at Children's Hospital Colorado in Aurora. “It's very exciting
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Amgen investors await weight-loss drug data [Yahoo! Finance]Yahoo! Finance
- Amgen investors await weight-loss drug data [Reuters]Reuters
- The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy [Yahoo! Finance Canada]Yahoo! Finance Canada
- Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes [Reuters]Reuters
- Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/3/23 - Beat
NVO
Sec Filings
- 5/1/24 - Form 6-K
- 4/26/24 - Form 6-K
- 4/25/24 - Form 6-K
- NVO's page on the SEC website